🍀 Happy St. Patrick's Day! NEW: Brave Butterfly - Bonds of Boston. How I paralleled my journey with Tatum's comeback. Adversity doesn't end the game—it teaches us how to begin.
As Patient #1 in the Transcon PTH clinical trial, I've been invited to share my story with pharmaceutical companies, healthcare professionals, and patient communities. These speaking engagements showcase how patient voices drive innovation and transform treatment options for hypoparathyroidism.
July 2021
How Wonderful the First 1-2 Years Were
In this powerful conversation with Ascendis Pharma, I share my experience as Patient #1 in the Transcon PTH clinical trial. I discuss how the first 1-2 years of treatment transformed my life, allowing me to experience recovery and hope after years of devastating decline. This session was requested by the company so they could see firsthand how their hard work and dedication to developing Transcon PTH (now Yorvipath) directly impacted a patient's life.
Key Topics:
January 2023
Yorvipath - A Breakthrough for Hypoparathyroidism
Celebrating the FDA approval of Yorvipath (Transcon PTH), the first and only PTH analog approved for hypoparathyroidism. After 5 years of dedication and commitment as Patient #1 in the clinical trial, I share my joy and gratitude for this groundbreaking therapy that transforms the standard of care for millions of patients worldwide.
Key Topics:
I'm available for speaking engagements, patient advocacy events, and healthcare conferences
Get in Touch